Myeloma Paper of the Day, August 4th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Myeloma patients with high baseline normal plasma cell ratios (≥5%) exhibit indolent features, lower tumor burden, reduced frequencies of cytopenias and immunoparesis and high-risk cytogenetics, and a favorable survival.”
Source: Robert Orlowski/X
Authors: Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Yuntong Liu, Jieqiong Zhou, Chenxing Du, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Xiaoqing Li, Xin Du, Yan Xu, Dehui Zou, Lugui Qiu, Mu Hao and Gang An.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.
